Posted on Authorea 9 Jul 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159431576.65318131 | This a preprint and has not been peer reviewed. Data may be preliminary. eew eotdteueo vbaiei h ramn fiipti Awihwsoiiae rmteLVS the from originated was which ablation. Report VA catheter idiopathic Case and of treatment AAD’s the multiple in to ivabradine ablation. resistant of catheter and use un- and the (AAD) primary reported drugs we the anti-arrhythmic other Here as to junc- considered compared treating profile were safety for automaticity better population relatively increased having pediatric which in in postural the mechanism in and trials derlying ectopic ivabradin clinical of atrial sinus role and randomized inappropriate promising tional large suggested with reports in patients case tested treating Previous for being used after syndrome frequently disease tachycardia is orthostatic artery it coronary addition, stable In and failure channels to (HCN) heart (I due current nucleotide-gated advancing cases. rate funny cyclic for of of success difficulties activated proportion inhibitor long-term anatomical high an (LMCA), in and is approach artery particular Ivabradine procedural epicardial coronary a lower of main pose necessity (LVS) left with the summit of VA associated and ventricular bifurcation suppress catheters are left the to the to and fails from proximity laboratory ablation originating its VA’s catheter the regard, relatively tools, in this with ablation challenge In effective guidelines and is side current patients. techniques ablation by some potential mapping therapy catheter in and in first-line hand, advances the other efficacy as technologic the Limited recommended treatment On the and AAD’s. and ablation. rates of clinics complications catheter use low long-term and the in (AAD) restrict encountered drugs effects frequently anti-arrhythmic are include (VA) options LVS ventricular the Idiopathic from originated was which VA idiopathic Introduction of treatment the ablation. in ivabradine. catheter ivabradine with and of treated AAD’s multiple successfully use to were the Recently, resistant who reported was disease. tachycardias we artery and ectopic an coronary case, junctional is stable present Ivabradine and and the atrial fraction effects. In ejection side with reduced to patients (HCN) with nucleotide-gated due described failure cyclic long-term cases heart hyperpolarization-activated used several of blocking be treatment by not the cells particular may pacemaker for a cardiac recommended AAD’s poses in and and (LVS) low (If) summit current is ventricular funny ablation left of catheter catheter the inhibitor or from for (AAD) originating success drugs is the anti-arrhythmic which as VA include challenge idiopathic options with treatment presenting and Patients common ablation. are (VA) arrhythmias ventricular Idiopathic Abstract 2020 9, July 1 G¨oksel Cinier Summit Ventricular Ventricular Left Idiopathic the with from Patient Originating a Arrhythmia in Ivabradine of Use The rSym re hrccadCrivsua ugr riigadRsac Hospital Research and Training Surgery Cardiovascular and Thoracic Ersek Siyami Dr 1 etHayıro˘glu Mert , 6-8 vbaieoesapasbetetetcoc yeetvl niiigI inhibiting effectively by choice treatment plausible a offers Ivabradine . 5 . 1 ai Ozcan Kazim , f ncricpcmkrclsb idn ohyperpolarization- to binding by cells pacemaker cardiac in ) 2 vbaiei urnl niae ntetetetof treatment the in indicated currently is Ivabradine . 1 1 he TEKKES Ahmet , IN ˙ 1 n ai Gurkan Kadir and , 1 oee,despite However, . f urn and current 3,4 1 . Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. fL yfnto a ierne eea aibe eepooe stepeitro V induced PVC of predictor coupling the short as and of QRS proposed wide absence were origin, the variables epicardial in several gender, male range, of burden, wide PVC development a high the including has for cardiomyopathy origin dysfunction factor of LV site risk epicardial of known of probability well disease catheters high heart advance a structural and to are arteries inability Arrhythmias coronary to PVC’s to due catheters. Frequent VA’s proximity VA’s ablation outflow interest, LV with other of of to accessible site 14.5% compared the easily approximately lower is to more are ablation constitute region VA’s catheter LVS is LVS The to the which directing LCX. inaccessible ablation from area is and which (AIV) originated inferior LAD area vein are more the interventicular superior the anterior more that and of and with of lateral perforator medial junction apex a septal a its arteries The regions; first at and (LCX) separate (GCV) the two circumflex ostium. vein to between LV left cardiac rise arch and of great giving the (LAD) aspect the by descending by superior anterior laterally formed most transected left is the of base at bifurcation its the located and were by region bounded visits triangular is a clinical triangle is Serial summit LV PVC’s. The suppressing further functions. for LV did and we BID burden asymptomatic, Discussion mg PVC was 10 patient of evaluation Considering to ECG the treatment. dose her for ivabradine ivabradine planned palpitations, to the prior no a recorded increase reported with was not hospital she that the one visit burden bpm from were the clinical PVC’s 79 discharged to Two effects the rate 12000 was side heart demonstrated In patient drug. mean no recording the a the Holter and later. with and of bpm week rhythm BID sinus effects 84 a mg normal side was showed visit 7.5 rate potential clinical to heart the outpatient increased mean was about planned the dose patient started showed significantly, we The ECG the improved previously, her with observed. patient complains and the counseling her palpitations by after later of used days BID were complaining that mg still medications was 5 5 various patient ivabradine least considering that at After PVC’s. procedure ablation. drop PVC’s. of the the frequent not suppression after of the did morning cessation achieve impedance the the to In case following failing ensued in after they W ended was suppressed, 50 transiently procedure to were The was up PVC’s power C W The Although was 45 5 arteries. Ablation seconds. temperature with coronary maximum match. from titrated a satisfactory distance with was showed mm with power proceed mapping 5 W region than pace to 30 more and endocardial to electrograms demonstrating found (LV) set after ventricular was ventricle area early ms) this left (-26 find to mapped signal was performed the not pre-QRS vein and could interventricular ms recorded (GCV)/anterior 26 we cusps vein be the with However, coronary cardiac could of great the signal side cusp. Lastly, ventricular septal assessed coronary ablation. early First, then left No We the catheter. irrigated USA). mapped. below regions. MN, tip was 3.5-mm Abbott, region these (RVOT) Precision, using from tract (EnSite by hours outflow system performed 72 ventricular mapping was over right 3D ablation PVC’s performed with and was 96000 ablation recording mapping revealed catheter Holter The and undergo disease. PVC’s to heart were of planned structural which was any burden QRS of the the signs of quantifying no segment for and initial functions the ventricular in origin right slurring epicardial and and and V3 LVS at of transition revealed suggestive precordial (ECG) early cardiac electrocardiography DII, count, to standard bigeminy blood compared 12-lead ventricular complete normal with panel. revealed rhythm hormone tests sinus thyroid Lab and unremarkable. in biochemistry was improvement history troponins, no family PVC’s. observing and frequent of after medical with ablation suppression Her catheter the diagnosed and for in been flecainide center failing isoptin, has our and beta-blocker, to She symptoms oral referred her was weeks. with patient before last months. The treated 12 during past and amiodarone. worsened for (PVC) but palpitation contractions with ventricular before clinic premature milder outpatient were arrhythmia our symptoms to Her presented female old years Eighteen 11 lhuhtetm nevlbtentefis igoi fPCsadteoccurrence the and PVC’s of diagnosis first the between interval time the Although . 9 rntoai coadorpy(T)dmntae omlleft normal demonstrated (TTE) echocardiography Transthoracic . Fgr 1A) (Figure ° n iigframnmm10 minimum a for aiming and Fgr 2B), (Figure 2 V’ a neirai ihRwv agri DIII in larger wave R with axis inferior had PVC’s . Fgr 1B) (Figure hc a infiatylwrcompared lower significantly was which n oPCs eet-w hour Seventy-two PVC’s. no and 10 Fgr 2A). (Figure ucs ae fcatheter of rates Success . Ω rpi meac.The impedance. in drop Fgr 3). (Figure Ω ihntefis 10 first the within h patient The narea An 9 . Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. V C prglto n eeoeet nato oeta uainbtentermt Vwl and wall LV remote the between duration potential action that in by I and heterogeneity supported receptors further and ryanodine was up-regulation of finding sensitivity 4 This calcium HCN in ivabradine. LV, increase administered the were prevented that partially rats ivabradine in infarction lower myocardial effects were non-reperfused inhibitory mortality after its h through 24 trig- within repolarization prevent VA may ventricular that ivabradine genes prolonging that hERG/I of is by on re-expression explanation arrhythmias be potential trigger mediated Another can conditions activity which channels. which en- gered possible that HCN production, to certain coding One for not cAMP predispose responsible is increased elucidated. are may it However, through myocytes be ivabradine. potential ventricular to by action prevented in yet spontaneous channels is and automaticity HCN after-depolarization increased of Elevated from by expression originating automaticity. caused tachycardias increased hanced of and that treatment node is the sinus in mechanism ivabradine than of AAD’s other other efficacy and areas to the compared underlying causing observed mechanisms by frequently Precise prolongation less interval much AAD’s QT it is of to makes it most lead which where inhibition, cardiomyopathy can AAD’s, hERG induced ivabradine other tachycardia Although unlike of by hemodynamics context contraindicated. therapy the on are in resynchronization effect particularly neutral cardiac option with attractive to profile an safety response good the has Ivabradine optimized and pacing biventricular blockers rate beta the side serious to increasing was to resistant due ivabradine them were report polymorphic using continue recent catecholaminergic that not more with could or a patient AAD’s In a other effects to rhythm. in resistant sinus was and arrhythmias who left to the ventricular convert suppressed from to successfully originating likely tachycardias to more atrial shown that were demonstrated independent appendage which study atria treatment, right (EP) the to electrophysiological response subsequent structural their underwent without of patients and All tachycardia atrial administration. focal ivabradine incessant with patients disease heart in treatment tachycardias ivabradine I evaluated atrial decreasing al and by in junctional effects fibrillation with inotropic atrial patients negative and without rhythm rate respectively sinus heart node in the are reduced who ivabradine patients that demonstrated reports Previous and veins adult pulmonary in and weaker cardiomyopathy respectively much dilated appendages node is and (AV) expression hypertrophy atrioventricular its ventricular and but as myocardium sinoatrial ventricular the infant myocardium in through explaining healthy abundant predominant action is dependent are isoform use 3 2 causing HCN HCN state and rates open heart 4 in higher HCN I are in inhibits they effectiveness and when greater channel diagnosis. only its HCN differential channels the the these magnetic of for blocks cardiac side Ivabradine performed have cytoplasmic not be to do could We binds which likely. Ivabradine configuration hospital, less QRS our diagnoses these and in made troponins (cMRI) patient cardiac imaging our for and normal resonance in course planned ARVD (ARVD) TTE, the for were dysplasia in atypical during ventricular visits was observed abnormalities right that clinical be structural dose arrhythmogenic can Serial of the sarcoidosis, PVC’s Absence Frequent increase including asymptomatic. . functions. not conditions was that LV did cardiac patient monitoring and We several the burden Holter of PVC PVC’s. because hour of 12000 BID 72 evaluation revealed further mg dysfunction. treatment the 10 LV ivabradine to subsequent the ivabradine of after of provided week risk only a the not PVC’s performed mitigated suppressing was also Thus, cardiomyopathy. but PVC relief developing of symptom risk the increased QRS wide interval 20 12 naptetwt o-shmcdltdcrimoah vbaieeetvl upesdPVC’s suppressed effectively ivabradine cardiomyopathy dilated non-ischemic with patient a In . Vdsucinwsntpeeti u ain u ihPCbre ihL pcriloii and origin epicardial LV with burden PVC high but patient our in present not was dysfunction LV . Kr 19 ovrint iu htmwsahee n1 u f2 ainsapoiaey4husafter hours 4 approximately patients 28 of out 17 in achieved was rhythm sinus to Conversion . hnes nteri iortmdl akeize l tde h ffc fiardn on ivabradine of effect the studied al. et Mackiewicz model, rat vivo in their In channels. 18 nsvrlcssadosrainlsuisiardn a sdscesul o treating for successfully used was ivabradine studies observational and cases several In . 15 hi xrsini etiua ycrimcnices ncrancniin such conditions certain in increase can myocardium ventricular in expression Their . β- 17 deegcsiuu a nraetessetblt fmoye oearly to myocytes of susceptibility the increase may stimulus adrenergic . 21 . 13 C hnesaeo smr HN14 n mn them among and 1-4) (HCN isomers 4 of are channels HCN . 6,7 nterpopciesnl etrsuyBnvlkret Banavalikar study center single prospective their In . 3 16 nadto,dffrn sfrsaefudi atrial in found are isoforms different addition, In . 23 hyfudta Aicdneadarrhythmic and incidence VA that found They . f f urn ncricpcmkrcells. pacemaker cardiac in current urn ntesnsnd n AV and node sinus the in current 22 . f urn nthe in current 14 . Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. 5 au ,LuW phfT ta.Ifcretadsotnosatvt nmueembryonic mouse in activity spontaneous and current f I al. physiological et T, and Opthof myocytes. regulation W, ventricular Liu cellular K, structure, Yasui 15. channels: HCN M. Ivabradine. Biel function. with C, Inhibition Wahl-Schott f 14. I AJ. Camm I, Savelieva heart 13. of Implications predictor ectopy: ventricular Frequent a HM. Haqqani Outcomes. as EP, and Gerstenfeld ectopy TE, Ventricular Walters A, al. Lee 12. et E, Vittinghoff death. TA, and Dewland failure JW, ablation. Dukes to relevant 11. concepts origi- anatomic arrhythmias summit Electrophysiology. summit: ventricular ventricular Idiopathic ventricular and left al. Arrhythmia left et ablate the H, and from Doppalapudi map nating HT, to McElderry T, How Yamada al. 10. et LC, Saenz F, Malavassi arrhythmias. A, Enriquez 9. Tachycardia. Atrial Left and Right Preli- Tekke¸sin A A 8. Surgery: Adjunct Cardiac an as Pediatric Ivabradine Following R. Tachycardia Ramamurthy Study. V, Ectopic minary Sharma S, Junctional Joshi Refractory to N, Tiwari due for G, tachycardiomyopathy Kumar of V, Kumar Reversal 7. A. ivabradine. Vasavda by P, tachycardia Parekh atrial Y, left Lokhandwala affected S, patients in Bohora coronary administration 6. stable ivabradine of in tachycardia. Efficacy Ivabradine sinus al. R. et inappropriate Ferrari A, by Sette M, M, Tendera Rebecchi Cal`o J-C, failure. L, 5. Tardif heart patients PG, clinical for Steg without Ivabradine I, disease Ford B. artery K, (BEAUTIFUL): Investigators Fox dysfunction R, Ferrari systolic 4. trial. left-ventricular M, placebo-controlled and Tendera double-blind, disease PG, randomised, artery Steg a coronary I, stable Ford with inhibition K, current Fox f I selective 3. ven- and specific on by lowering consensus rate expert ivabradine. Heart JA. with EHRA/HRS/APHRS Camm D, al. DiFrancesco et 2. J, Kalman GN, arrhythmias. to Kay tricular and CT, ivabradine Pedersen from 1. most trials benefit clinical would response Randomized that clinical iv) particu- REFERENCES population finally, in in patient and channels heterogeneity strategies. specific arrhythmias HCN for dosing identify of specific optimal reasons better isoforms determine of the rec- Which to pathogenesis other are iii) needed myocytes before the What in are in addressed arrhythmias? ii) HCN contributory be cardiac of are with to regulated? expression catheter lar patients issues increased it and among the several is AAD’s ivabradine drives are how other to What case there and i) in However, cells context: used pacemaker this VA’s. be in may idiopathic ivabradine ivabradine suppress ommending profile as to safety considered fails were acceptable and ablation its infarction with myocardial conclusion, after In h . 24 by within caused observed mechanisms were pro-arrhythmic all major which zone, border infarct elMlLf Sci. Life Mol Cell er Rhythm. Heart ,GuknK le T T¨urkkan AT, C, G¨urkan Alper I, K, ˙ ol ora o eiti n ogntlHatSurgery. Heart Congenital and Pediatric for Journal World er,Ln n Circulation. and Lung Heart, Drugs. mCl Cardiol. Coll Am J Europace. icRes. Circ 2004;64(16):1757-1765. 2009;66(3):470. 2017;14(1):141-148. 2001;88(5):536-542. 2014;16(9):1257-1283. 2010;3(6):616-623. mCl Cardiol. Coll Am J er Rhythm. Heart adoacElectrophysiol. Cardiovasc J 2015;66(2):101-109. nlJMed. J Engl N 2019;28(1):178-190. 4 zignN vbaieTriae Incessant Terminated Ivabradine N. Ozbilgin ¨ 2010;7(9):1318-1323. h Lancet. The 036(8Splmn 2):C47-C48. Supplement 2013;62(18 rgSaf. Drug 2014;371(12):1091-1099. 2008;372(9641):807-816. 2011;22(3):340-342. 2008;31(2):95-107. 2019;10(6):709-714. Circulation: Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. -:Tredmninl C:Eetoadorpy G:Eetorm C:Getcricvein. cardiac Great GCV: Electrogram, EGM: Electrocardiography, ECG: dimensional, Three 3-D: recordings. QRS ECG surface the to GCV. distal the panel: Top 3: Figure 2B: 2A: Figure Electrocardiography. ECG: 1B: 1A: Figure Figures rat. arrhythmias for ventricular the Legends HCN against in protects the Ivabradine infarction al. by myocardial et S, blockade acute Chu in channel JY, Gerges potassium U, Mackiewicz hERG 23. al. et C, ivabradine. agent Zhang 2015;4(4):e001813. bradycardic ec- KE, inhibitor ventricular Brack channel premature D, of Melgari suppression cardiomyopathy.22. Significant dilated J. in Khoo ivabradine AR, with Houghton topics ivab- to LH, with refractory Mughal suppression tachycardia 21. arrhythmia ventricular Ventricular polymorphic sympathectomy. HM. catecholaminergic and Nayak with flecainide, AD, patient nadolol, Beaser a Z, in Aziz radine U, Kohli 20. rate Corre- Electrophysiological for Tachycardia. and ivabradine Atrial Clinical trophysiology. Ivabradine-Sensitive of al. Incessant et role D, of Padmanabhan Emerging lates J, WD. beats Shenthar B, Jr Banavalikar ectopic 19. Cahoon by DK, fibrillation. fibrillation Lowe atrial atrial KE, in Francis control of pharmacological SL, Initiation Turley characteristics, ablation. al. 18. electrophysiological radiofrequency et of veins: effects C-T, pulmonary and Tai and responses, normal the M-H, in from Hsieh (If) current originating S-A, funny of Chen basis 17. Molecular al. et S, heart. Zicha human G, failing Lonardo F, Stillitano 16. 2Hu otrrcrigo h ain fe vbaietreatment. ivabradine after patient the of recording Holter 72-Hour treatment. ivabradine after patient the of recording ECG surface 12-Lead 2Hu otrrcrigo h ain ro oiardn treatment. ivabradine to prior patient the of recording Holter 72-Hour treatment. ivabradine to prior patient the of recording ECG surface 12-Lead otmpanel: Bottom 2019;12(8):e007387. ciainmpigi h - ytmsoigtest fteeris ciainin activation earliest the of site the showing system 3-D the in mapping Activation o elCardiol. Cell Mol J hrAvCrivs Dis. Cardiovasc Adv Ther oa G’ ttealto ahtrsoserysgas(2 s relative ms) (-26 signals early shows catheter ablation the at EGM’s Local aigCi Electrophysiol. Clin Pacing 2008;45(2):289-299. elPhysiol. Cell J 5 ora fteAeia er Association. Heart American the of Journal Circulation. 2016;10(6):348-352. 2014;229(6):813-823. iclto:Aryhi n Elec- and Arrhythmia Circulation: 1999;100(18):1879-1886. 2020. Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. 6 Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. 7 Posted on Authorea 9 Jul 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.159431576.65318131 — This a preprint and has not been peer reviewed. Data may be preliminary. 8